A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

NCT06788509 PHASE1 ENROLLING_BY_INVITATION

The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the blood and bone marrow in which the bone marrow makes a large number of abnormal blood cells) and advanced solid tumors and metastatic castration-resistant prostate cancer (mCRPC).

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	PHASE1
Status	ENROLLING_BY_INVITATION
Enrolment	120
Start date	Mon Dec 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Leukemia, Myeloid, Acute
• Leukemia, Lymphocytic, Chronic, B-Cell
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndromes
• Neoplasms
• Solid Tumor, Adult
• Prostatic Neoplasms, Castration-Resistant

Interventions

• JNJ-75348780
• JNJ-67856633
• JNJ-54179060
• JNJ-64264681
• JNJ-74856665
• JNJ-70218902
• JNJ-64619178
• JNJ-80948543
• JNJ-87801493

Countries

Georgia, France, Japan, Greece, Ukraine, Belgium, Taiwan, United Kingdom, Israel, Moldova, Poland, South Korea, Spain